克罗恩病内镜下缓解的定义:与疾病进展低风险相关的MM-SES-CD和SES-CD阈值
本研究利用CALM长期扩展研究61例早期克罗恩病患者作为推导队列,并以McMaster炎症性肠病数据库99例患者验证,确定与长期疾病进展低风险相关的最佳MM-SES-CD阈值为<22.5、SES-CD阈值为<4,上述阈值在验证队列中得到确认。
要点
- MM-SES-CD<22.5与疾病进展低风险相关,预测疾病进展的曲线下面积为0.81(95%CI 0.68-0.94;P<.001)。
- 推导队列中MM-SES-CD≥22.5者疾病进展比例显著高于<22.5者(10/17[58.8%] vs 3/44[6.8%];P<.001)。
- 推导队列中SES-CD≥4者疾病进展比例显著高于<4者(11/25[44.0%] vs 2/36[5.6%];P<.001)。
核心结论
- 在回结肠型或结肠型克罗恩病患者中,达到MM-SES-CD<22.5或SES-CD<4与疾病进展低风险相关,可能是临床试验和实践中内镜下愈合的合适目标。
研究设计与样本
- 研究使用CALM长期扩展研究中61例早期克罗恩病患者作为推导队列,并以McMaster炎症性肠病数据库99例患者进行验证。
- 主要结局为自CALM试验结束以来的疾病进展,包括新发内瘘/脓肿、狭窄、肛瘘或脓肿、克罗恩病相关住院或手术。
- 最佳MM-SES-CD和SES-CD阈值通过最大约登指数确定,并用受试者工作特征曲线分析比较不同缓解定义阈值对疾病进展的预测。
主要发现
- 推导队列中,基于最大约登指数,与疾病进展低风险相关的最佳阈值为MM-SES-CD<22.5和SES-CD<4。
- 推导队列中MM-SES-CD≥22.5者疾病进展比例显著高于<22.5者(10/17[58.8%] vs 3/44[6.8%];P<.001)。
- 推导队列中SES-CD≥4者疾病进展比例显著高于<4者(11/25[44.0%] vs 2/36[5.6%];P<.001)。
- 与其他临床或内镜缓解定义相比(这些定义准确性差至中等),MM-SES-CD<22.5预测疾病进展表现最佳(曲线下面积=0.81;95%CI 0.68-0.94;P<.001)。
- 上述阈值在验证队列中得到确认。
关键数值与推荐
- MM-SES-CD<22.5为与疾病进展低风险相关的最佳阈值。
- SES-CD<4为与疾病进展低风险相关的最佳阈值。
- MM-SES-CD<22.5预测疾病进展的曲线下面积为0.81(95%CI 0.68-0.94;P<.001)。
临床怎么用
- 在回结肠型或结肠型克罗恩病患者中,达到MM-SES-CD<22.5或SES-CD<4与疾病进展低风险相关,可能是临床试验和实践中内镜下愈合的合适目标。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We assessed Modified Multiplier Simple Endoscopic Score for Crohn's Disease (MM-SES-CD) and Simple Endoscopic Score for Crohn's Disease (SES-CD) thresholds that are best associated with low likelihood of long-term disease progression. METHODS: Data from 61 patients with early Crohn's disease (CD) who participated in the CALM long-term extension study were used as the derivation cohort and validated using the McMaster inflammatory bowel disease database (n = 99). The primary outcome was disease progression (new internal fistula/abscess, stricture, perianal fistula or abscess, CD-related hospitalization or surgery) since the end of the CALM trial. Optimal MM-SES-CD and SES-CD thresholds were determined using the maximum Youden index. Receiver operating characteristic curve analyses compared threshold scores of remission definitions on disease progression. RESULTS: In the derivation cohort, based on the maximum Youden index, the optimal thresholds associated with a low likelihood of disease progression were MM-SES-CD <22.5 and SES-CD <4. A significantly greater proportion of patients with a MM-SES-CD ≥22.5 had disease progression as compared with patients in the derivation cohort with MM-SES-CD <22.5 (10/17 [58.8%] vs 3/44 [6.8%]; P < .001). Similarly, a significantly greater number of patients with SES-CD ≥ 4 had disease progression compared with those with a SES-CD <4 (11/25 [44.0%] vs 2/36 [5.6%]; P < .001). Compared with other clinical or endoscopic remission definitions, which demonstrated poor to fair accuracy, MM-SES-CD <22.5 performed the best for predicting disease progression (area under the curve = 0.81; 95% confidence interval, 0.68-0.94; P < .001). These thresholds were confirmed in the validation cohort. CONCLUSION: Achievement of MM-SES-CD <22.5 or SES-CD <4 in patients with ileocolonic or colonic CD is associated with low risk of disease progression and may be suitable targets in clinical trials and practice for endoscopic healing.
引用
- Narula N, Wong ECL, Dulai PS, et al. Defining Endoscopic Remission in Crohn's Disease: MM-SES-CD and SES-CD Thresholds Associated With Low Risk of Disease Progression. Clin Gastroenterol Hepatol. 2024. PMID: 38428709. doi:10.1016/j.cgh.2024.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。